JPS5625169A - Triazine derivative - Google Patents

Triazine derivative

Info

Publication number
JPS5625169A
JPS5625169A JP7158080A JP7158080A JPS5625169A JP S5625169 A JPS5625169 A JP S5625169A JP 7158080 A JP7158080 A JP 7158080A JP 7158080 A JP7158080 A JP 7158080A JP S5625169 A JPS5625169 A JP S5625169A
Authority
JP
Japan
Prior art keywords
triazine derivative
triazine
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP7158080A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0144706B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html
Inventor
Jiyooji Batsukusutaa Maachin
Reginarudo Erufuitsuk Arubaato
Ainsurii Miraa Arisuteaa
Aran Sooyaa Debitsudo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10505597&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPS5625169(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of JPS5625169A publication Critical patent/JPS5625169A/ja
Publication of JPH0144706B2 publication Critical patent/JPH0144706B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/15—Preparation of carboxylic acids or their salts, halides or anhydrides by reaction of organic compounds with carbon dioxide, e.g. Kolbe-Schmitt synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/363—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP7158080A 1979-06-01 1980-05-30 Triazine derivative Granted JPS5625169A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB7919257 1979-06-01

Publications (2)

Publication Number Publication Date
JPS5625169A true JPS5625169A (en) 1981-03-10
JPH0144706B2 JPH0144706B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1989-09-29

Family

ID=10505597

Family Applications (2)

Application Number Title Priority Date Filing Date
JP7158080A Granted JPS5625169A (en) 1979-06-01 1980-05-30 Triazine derivative
JP12137085A Granted JPS6133163A (ja) 1979-06-01 1985-06-04 トリアジン誘導体製造用の新規中間体化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP12137085A Granted JPS6133163A (ja) 1979-06-01 1985-06-04 トリアジン誘導体製造用の新規中間体化合物

Country Status (30)

Country Link
US (2) US4486354A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP0021121B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JPS5625169A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR227521A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) AT370097B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU530999B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG60427B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1112643A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS (1) CS234018B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ384891A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD (1) DD151309A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK153787C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES8104993A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI67844C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GE (1) GEP19960470B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR68380B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU182086B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE49823B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL60201A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1147087B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9202962A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY8500062A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL950007I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ193890A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL124029B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SU (1) SU1055331A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA5576A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU145680A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA803250B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZW (1) ZW12980A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018524302A (ja) * 2015-06-12 2018-08-30 ユニバーシティ オブ グリニッジ インターフェロン‐γ阻害剤としてのトリアジン誘導体

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3069556D1 (en) * 1979-08-16 1984-12-06 Wellcome Found Solid pharmaceutical formulation containing substitued phenyl-triazines
GB8328757D0 (en) * 1983-10-27 1983-11-30 Wellcome Found Chemical compounds
DE3600891A1 (de) * 1986-01-15 1987-07-16 Bayer Ag 1,8-verbrueckte 4-chinolon-3-carbonsaeuren und diese enthaltende arzneimittel
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
US4972496A (en) * 1986-07-25 1990-11-20 Grid Systems Corporation Handwritten keyboardless entry computer system
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
GB9012311D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
DE4290300T1 (de) * 1991-01-30 1993-10-07 Wellcome Found Wasserdispergierbare Tabletten
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
GB9124807D0 (en) * 1991-11-22 1992-01-15 Wellcome Found Pharmaceutical formulations
GB9203483D0 (en) * 1992-02-19 1992-04-08 Wellcome Found Anti-inflammatory compounds
DE69307705T2 (de) * 1992-06-12 1997-05-22 Wellcome Found Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4,-triazinisethionat zur behandlung und vorbeugung von drogenabhaengigkeit,-toleranz und- sensibilisierung
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
FR2699077B1 (fr) * 1992-12-16 1995-01-13 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
US5866597A (en) * 1993-03-19 1999-02-02 Glaxo Wellcome Inc. Use of triazine compounds for the treatment of memory and learning disorders
GB9305692D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
GB9305693D0 (en) * 1993-03-19 1993-05-05 Wellcome Found Therapeutic triazine compounds and use
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
GB9317146D0 (en) * 1993-08-18 1993-10-06 Wellcome Found Therapeutic combinations
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9426448D0 (en) * 1994-12-30 1995-03-01 Wellcome Found Process
DE69527153T2 (de) * 1994-12-30 2002-12-19 The Wellcome Foundation Ltd., Greenford Verfahren zur herstellung von lamotrigine
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
GB9518027D0 (en) * 1995-09-05 1995-11-08 Wellcome Found Pharmacologically active compound
FR2741879A1 (fr) * 1995-12-05 1997-06-06 Esteve Labor Dr Derives de fluorophenyl-triazines et pyrimidines, leur preparation et leur application en tant que medicament
US6202491B1 (en) 1997-07-22 2001-03-20 Skf Condition Monitoring, Inc. Digital vibration coupling stud
GB9726987D0 (en) * 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
US6124500A (en) * 1998-03-09 2000-09-26 Rohm And Haas Company Process for synthesizing benzoic acids
GB9812413D0 (en) 1998-06-10 1998-08-05 Glaxo Group Ltd Compound and its use
IN183150B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1998-12-14 1999-09-25 Torrent Pharmaceuticals Ltd
CA2334937C (en) * 1998-12-14 2004-09-21 Torrent Pharmaceuticals Ltd. An improved process for the preparation of 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
US20020055177A1 (en) * 1999-03-10 2002-05-09 Glaxo Wellcome Inc. Compound and its use
JP2002541215A (ja) * 1999-04-09 2002-12-03 ユーロ−セルティック エス． ア． ナトリウムチャネル遮断薬組成物およびその使用
GB9907965D0 (en) 1999-04-09 1999-06-02 Glaxo Group Ltd Medical use
WO2001049669A1 (en) * 2000-01-03 2001-07-12 Rpg Life Sciences Limited A process for the preparation of 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine, commonly known as lamotrigine
IL134730A (en) * 2000-02-25 2003-10-31 Chemagis Ltd Process for preparing substituted benzoyl cyanide amidinohydrazones
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
AP2001002359A0 (en) 2000-11-30 2001-12-31 Pfizer Prod Inc Combination of gaba agonists and aldose reductase inhibitors.
EA200300432A1 (ru) 2000-11-30 2003-10-30 Пфайзер Продактс Инк. Комбинация гамк-агонистов и ингибиторов сорбитолдегидрогеназы
JP2004526714A (ja) * 2001-02-27 2004-09-02 テバ ファーマシューティカル インダストリーズ リミティド ラモトリジンの新しい結晶形およびそれらの調製方法
DK1423168T3 (da) * 2001-09-03 2006-05-15 Newron Pharm Spa Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse
CA2366521C (en) 2001-12-24 2007-03-06 Brantford Chemicals Inc. A new and efficient process for the preparation of lamotrigine and related 3,5-diamino-6-substituted-1,2,4-triazines
EP1496864B1 (en) * 2002-04-23 2007-03-21 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing lamotrigine particles of defined morphology
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
HU225667B1 (en) 2002-09-20 2007-05-29 Richter Gedeon Nyrt Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
ES2209639B1 (es) 2002-10-31 2005-08-01 Vita Cientifica, S.L. Procedimiento para la obtencion de un compuesto farmaceuticamente activo y obtencion de su intermedio.
AU2003217437A1 (en) * 2003-03-17 2004-10-11 Hetero Drugs Limited Novel crystalline forms of lamotrigine
WO2004085426A1 (en) 2003-03-27 2004-10-07 Hetero Drugs Limited Novel crystalline forms of candesartan cilexetil
BRPI0410271A (pt) 2003-05-16 2006-05-16 Pfizer Prod Inc combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas
WO2004103340A1 (en) * 2003-05-20 2004-12-02 Ranbaxy Laboratories Limited Water dispersible tablets of lamotrigine
GB2395483A (en) * 2003-07-03 2004-05-26 Jubilant Organosys Ltd Crystalline lamotrigine and its monohydrate
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
WO2005082372A1 (en) * 2004-01-29 2005-09-09 Pfizer Products Inc. COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
ME01801B (me) * 2004-09-10 2011-02-28 Newron Pharm Spa UPOTREBA (R)-(HALOBENZILOKSI) BENZILAMINO-PROPANAMIDA KAO SELEKTIVNIH MODULATORA NATRIJUMOVIH l/ILI KALCIJUMOVIH KANALA
US7825151B2 (en) * 2005-09-23 2010-11-02 Janssen Pharmaceutica Nv Hexahydro-cyclooctyl pyrazole cannabinoid modulators
US8378117B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
WO2007044215A1 (en) * 2005-09-23 2007-04-19 Janssen Pharmaceutica, N.V. Hexahydro cyclooctyl pyrazole cannabinoid modulators
ATE534387T1 (de) * 2005-09-23 2011-12-15 Janssen Pharmaceutica Nv Hexahydro-cycloheptapyrazol-cannabinoid- modulatoren
US8378096B2 (en) * 2005-09-23 2013-02-19 Janssen Pharmaceutica N.V. Hexahydro-cycloheptapyrazole cannabinoid modulators
AU2006292051B2 (en) 2005-09-23 2012-11-15 Janssen Pharmaceutica, N.V. Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
US20070117858A1 (en) * 2005-11-23 2007-05-24 Mingde Xia Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators
EP1979593B1 (en) * 2006-02-03 2017-12-06 Rolls-Royce Corporation Gas turbine engine fuel system with fuel metering valve
US7795294B2 (en) * 2006-02-14 2010-09-14 Janssen Pharmaceutica N.V. Tetrahydro-2H-indazole pyrazole cannabinoid modulators
US20070254911A1 (en) * 2006-03-27 2007-11-01 Mingde Xia Tetrahydro-Pyrazolo[3,4-c]Pyridine Cannabinoid Modulators
WO2007112402A1 (en) * 2006-03-27 2007-10-04 Janssen Pharmaceutica N.V. Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
WO2007122638A2 (en) * 2006-04-26 2007-11-01 Ratnamani Bio-Chemicals & Pharmaceuticals Pvt. Ltd. An improved process for preparation of lamotrigine intermediates
EP2024345B1 (en) * 2006-05-31 2009-12-16 Calaire Chimie SAS Method for preparing lamotrigine and its intermediate 2,3-dichlorobenzoyl chloride
GB0613836D0 (en) 2006-07-13 2006-08-23 Univ Greenwich New medical use of triazine derivatives
US20120142919A1 (en) 2006-08-02 2012-06-07 Medichem, S.A. Method for synthesizing lamotrigine
EP2054396A1 (en) * 2006-08-14 2009-05-06 Lonza Ag A process for the preparation of lamotrigine
MX2009007916A (es) 2007-01-24 2009-07-31 Glaxo Group Ltd Composiciones farmaceuticas que comprenden 3,5-diamino-6-(2,3-dicl orofenil)-l,2,4,-triazina; o r(-)-2,4-diamino-5-(2,3-diclorofenil) -6-fluorometil pirimidina y un receptor neuroquinina 1.
US7943653B2 (en) * 2007-08-13 2011-05-17 Janssen Pharmaceutica N.V. Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators
US20090076010A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched lamotrigine
WO2009061513A1 (en) * 2007-11-09 2009-05-14 Thar Pharmaceuticals Crystalline forms of lamotrigine
GB0800741D0 (en) 2008-01-16 2008-02-20 Univ Greenwich Cyclic triazo and diazo sodium channel blockers
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
CN102421763B (zh) 2009-05-13 2015-06-17 尼克塔治疗公司 含有寡聚体的取代的芳族三嗪化合物
US20100297195A1 (en) 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Controlled release lamotrigine formulations
GB2471729A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
GB2471713A (en) 2009-07-08 2011-01-12 Univ Greenwich 1,2,4-triazine derivatives and their use as sodium channel blockers
US20110052686A1 (en) * 2009-09-03 2011-03-03 Ranbaxy Laboratories Limited Modified release lamotrigine tablets
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
WO2013183985A1 (en) 2012-06-05 2013-12-12 Erasmus University Medical Center Rotterdam Method of treating cognitive impairment and compounds for use therein
US10189859B2 (en) 2013-12-21 2019-01-29 Nektar Therapeutics Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine
ES2908641T3 (es) 2016-12-16 2022-05-03 Idorsia Pharmaceuticals Ltd Combinación farmacéutica que comprende un bloqueador del canal del calcio de tipo T
TWI826531B (zh) 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB759014A (en) * 1952-02-26 1956-10-10 Wellcome Found Improvements in triazines and their manufacture
AT190941B (de) * 1954-09-22 1957-07-25 Chemie Linz Ag Verfahren zur Herstellung neuer Guanylhydrazone
US2952677A (en) * 1956-10-01 1960-09-13 Ici Ltd Aminoguanadine compounds
BE663481A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1964-05-05
GB1204631A (en) * 1967-10-12 1970-09-09 Shell Int Research Pharmacologically active benzylideneamino guanidines and their use
GB1223491A (en) * 1967-10-13 1971-02-24 American Home Prod Guanidines
US3637688A (en) * 1970-01-09 1972-01-25 American Home Prod 6-(fluoro and trifluoromethyl phenyl)-3 5-diamino - 1 2 4 - triazines and substituted - 6 - phenylalkyl-3,5-diamino-1 2 4-triazines
DE3069556D1 (en) * 1979-08-16 1984-12-06 Wellcome Found Solid pharmaceutical formulation containing substitued phenyl-triazines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018524302A (ja) * 2015-06-12 2018-08-30 ユニバーシティ オブ グリニッジ インターフェロン‐γ阻害剤としてのトリアジン誘導体

Also Published As

Publication number Publication date
IL60201A (en) 1984-05-31
AR227521A1 (es) 1982-11-15
ATA289680A (de) 1982-07-15
AU5890680A (en) 1980-12-04
EP0021121B1 (en) 1983-05-11
NL950007I2 (nl) 1997-02-03
PL224633A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1981-02-13
PL124029B1 (en) 1982-12-31
FI67844B (fi) 1985-02-28
SU1055331A3 (ru) 1983-11-15
IE49823B1 (en) 1985-12-25
DK153787B (da) 1988-09-05
NZ193890A (en) 1984-07-06
JPS6133163A (ja) 1986-02-17
DD151309A5 (de) 1981-10-14
FI67844C (fi) 1985-06-10
US4602017A (en) 1986-07-22
ZW12980A1 (en) 1982-01-06
MX9202962A (es) 1992-07-01
CS234018B2 (en) 1985-03-14
UA5576A1 (uk) 1994-12-28
HU182086B (en) 1983-12-28
CZ384891A3 (en) 1993-10-13
IT8048848A0 (it) 1980-05-30
MY8500062A (en) 1985-12-31
AU530999B2 (en) 1983-08-04
ES491998A0 (es) 1981-05-16
JPH0144179B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1989-09-26
AU566870B2 (en) 1987-11-05
US4486354A (en) 1984-12-04
IT1147087B (it) 1986-11-19
YU145680A (en) 1983-02-28
NL950007I1 (nl) 1995-06-16
EP0059987B1 (en) 1985-08-14
ZA803250B (en) 1982-01-27
IE801126L (en) 1980-12-01
EP0021121A1 (en) 1981-01-07
GR68380B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1981-12-28
DK233880A (da) 1980-12-02
BG60427B2 (bg) 1995-03-31
JPH0144706B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1989-09-29
IL60201A0 (en) 1980-07-31
ES8104993A1 (es) 1981-05-16
AT370097B (de) 1983-02-25
DK153787C (da) 1989-01-16
GEP19960470B (en) 1996-08-29
FI801758A7 (fi) 1980-12-02
EP0059987A1 (en) 1982-09-15
CA1112643A (en) 1981-11-17

Similar Documents

Publication Publication Date Title
JPS5625169A (en) Triazine derivative
GB2055813B (en) Aminoalkylbenzene derivatives
GB2054560B (en) Benzylimdiazole derivatives
GB2058765B (en) Deformyltylosin derivatives
GB2043639B (en) 3-optionally substituted methyl-2-penem derivatives
JPS55130981A (en) Oxapenem derivative
JPS5651456A (en) 22phenyltetraline derivative
JPS5690084A (en) Benzimidazolinone derivative
GB2046734B (en) 7-(-oximino-pyrazolyl(-acetamido)-cephen derivatives
JPS5625170A (en) Triazine derivative
JPS5625152A (en) 33methyleneazetizine derivative
CU35300A (en) Pyrrholidine derivatives
JPS55160778A (en) Imidazobenzodiazepine derivative
GB2065111B (en) Decaprenylamine derivatives
JPS55120571A (en) Heterocyclic derivative
JPS56124000A (en) Steroiddspiroooxazolidinone derivative
GB2062464B (en) Eburnamenine derivatives
GB2053899B (en) Terahydrophthalamide derivatives
GB2055368B (en) E-homoeburnane derivatives
JPS5692844A (en) Novel 22aminoethanol derivative
GB2047703B (en) Oxa-lactam derivative
JPS5651448A (en) 155sulfonamidoprostaglandin derivative
GB2059954B (en) 1-phenethylimidazole derivatives
GB2050377B (en) Pyrazinoquinoxaline derivatives
GB2047707B (en) Oxa-lactam derivative